FDAapproval65% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for atomoxetine.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Sleep Medicine · Obstructive Sleep Apnea
- Sub-indication
- General
Related signal: Study Compares PAP Therapy, Dental Device, and Atomoxetine-Oxybutynin for OSA Treatment